| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| BWAYBrainsWay Ltd. | 452.42M | 23.10 | 128.33 | 29.04% | 12.73% | 8.92% | 1.44% | 0.09 |
| INSPInspire Medical Systems, Inc. | 2.8B | 96.47 | 55.13 | 28.49% | 5.05% | 6.69% | 3.25% | 0.05 |
| TIVCTivic Health Systems, Inc. | 3.11M | 1.23 | -0.06 | -33.67% | -15.57% | -134.25% | ||
| COCHEnvoy Medical, Inc. | 19.42M | 0.67 | -0.45 | -28.8% | -104.75% | |||
| HSDTSolana Company | 128.03M | 3.10 | -0.72 | -19.25% | -393.59% | -6.89% | 0.01 | |
| NXLNexalin Technology, Inc. | 12.87M | 0.69 | -0.83 | 52.35% | -55.3% | -182.01% | ||
| CVRXCVRx, Inc. | 143.37M | 5.47 | -2.06 | 30.53% | -92.95% | -108.26% | 0.71 | |
| VANIVivani Medical, Inc. | 91.92M | 1.26 | -2.93 | -19.88% | 1.10 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Sales/Revenue | 36.97M | 41.14M | 45.18M | 45.52M | 65.42M | 79.91M |
| Revenue Growth % | - | 0.11% | 0.1% | 0.01% | 0.44% | 0.22% |
| Cost of Goods Sold | 10.51M | 10.87M | 11.75M | 13.03M | 17.3M | 20.82M |
| COGS % of Revenue | 0.28% | 0.26% | 0.26% | 0.29% | 0.26% | 0.26% |
| Gross Profit | 26.46M | 30.27M | 33.44M | 32.49M | 48.12M | 59.09M |
| Gross Margin % | 0.72% | 0.74% | 0.74% | 0.71% | 0.74% | 0.74% |
| Gross Profit Growth % | - | 0.14% | 0.1% | -0.03% | 0.48% | 0.23% |
| Operating Expenses | 48.49M | 43.32M | 57.17M | 73.29M | 75.3M | 80.76M |
| OpEx % of Revenue | 1.31% | 1.05% | 1.27% | 1.61% | 1.15% | 1.01% |
| Selling, General & Admin | 30.2M | 27.63M | 38.96M | 51.34M | 54.52M | 57.1M |
| SG&A % of Revenue | 0.82% | 0.67% | 0.86% | 1.13% | 0.83% | 0.71% |
| Research & Development | 18.29M | 15.7M | 18.21M | 21.95M | 20.78M | 23.65M |
| R&D % of Revenue | 0.49% | 0.38% | 0.4% | 0.48% | 0.32% | 0.3% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -22.03M | -13.05M | -23.74M | -40.79M | -27.17M | -21.67M |
| Operating Margin % | -0.6% | -0.32% | -0.53% | -0.9% | -0.42% | -0.27% |
| Operating Income Growth % | - | 0.41% | -0.82% | -0.72% | 0.33% | 0.2% |
| EBITDA | -21.61M | -12.74M | -23.44M | -37.81M | -25.57M | -19.9M |
| EBITDA Margin % | -0.58% | -0.31% | -0.52% | -0.83% | -0.39% | -0.25% |
| EBITDA Growth % | - | 0.41% | -0.84% | -0.61% | 0.32% | 0.22% |
| D&A (Non-Cash Add-back) | 421K | 312K | 296K | 2.99M | 1.6M | 1.77M |
| EBIT | -20.49M | -12.79M | -28.67M | -39.55M | -24.44M | -18.34M |
| Net Interest Income | -9.22M | -11.45M | -6.96M | -5.95M | -5.47M | -5.77M |
| Interest Income | 261K | 41K | 448K | 1.58M | 3.05M | 3.02M |
| Interest Expense | 9.48M | 11.49M | 7.41M | 7.53M | 8.52M | 8.8M |
| Other Income/Expense | -7.94M | -11.23M | -12.34M | -6.29M | -5.78M | -5.47M |
| Pretax Income | -29.97M | -24.28M | -36.08M | -47.08M | -32.96M | -27.14M |
| Pretax Margin % | -0.81% | -0.59% | -0.8% | -1.03% | -0.5% | -0.34% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -29.97M | -24.28M | -36.08M | -47.08M | -32.96M | -27.14M |
| Net Margin % | -0.81% | -0.59% | -0.8% | -1.03% | -0.5% | -0.34% |
| Net Income Growth % | - | 0.19% | -0.49% | -0.3% | 0.3% | 0.18% |
| Net Income (Continuing) | -29.97M | -24.28M | -36.08M | -47.08M | -32.96M | -27.14M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.70 | -2.17 | -2.17 | -1.91 | -1.27 | -0.93 |
| EPS Growth % | - | 0.2% | 0% | 0.12% | 0.34% | 0.27% |
| EPS (Basic) | -2.70 | -2.17 | -2.17 | -1.91 | -1.27 | -0.93 |
| Diluted Shares Outstanding | 11.1M | 11.1M | 16.61M | 24.59M | 25.85M | 29.13M |
| Basic Shares Outstanding | 11.1M | 11.1M | 16.61M | 24.59M | 25.85M | 29.13M |
| Dividend Payout Ratio | - | - | - | - | - | - |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 20.26M | 54.56M | 132.82M | 97.71M | 92.72M | 81.34M |
| Cash & Short-Term Investments | 5.09M | 38.08M | 115.58M | 77.41M | 66.45M | 52.76M |
| Cash Only | 4.12M | 26.39M | 19.19M | 6.61M | 18.06M | 13.43M |
| Short-Term Investments | 969K | 11.69M | 96.4M | 70.8M | 48.4M | 39.33M |
| Accounts Receivable | 6.02M | 8.39M | 7.09M | 7.48M | 12.31M | 12.85M |
| Days Sales Outstanding | 59.4 | 74.49 | 57.28 | 59.99 | 68.7 | 58.7 |
| Inventory | 7.9M | 6.91M | 7.82M | 9.71M | 11.21M | 13.38M |
| Days Inventory Outstanding | 274.41 | 232.08 | 243.02 | 272.12 | 236.61 | 234.57 |
| Other Current Assets | 0 | 0 | 0 | 3.11M | 2.74M | 2.35M |
| Total Non-Current Assets | 835K | 1.39M | 746K | 16.39M | 14.93M | 13.31M |
| Property, Plant & Equipment | 810K | 515K | 603K | 15.9M | 14.41M | 12.89M |
| Fixed Asset Turnover | 45.64x | 79.88x | 74.93x | 2.86x | 4.54x | 6.20x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 25K | 873K | 143K | 490K | 524K | 413K |
| Total Assets | 21.09M | 55.95M | 133.56M | 114.11M | 107.65M | 94.65M |
| Asset Turnover | 1.75x | 0.74x | 0.34x | 0.40x | 0.61x | 0.84x |
| Asset Growth % | - | 1.65% | 1.39% | -0.15% | -0.06% | -0.12% |
| Total Current Liabilities | 75.15M | 9.6M | 9.3M | 10.98M | 16.23M | 15.16M |
| Accounts Payable | 903K | 949K | 1.38M | 2.15M | 2.33M | 2.95M |
| Days Payables Outstanding | 31.37 | 31.88 | 42.81 | 60.16 | 49.2 | 51.78 |
| Short-Term Debt | 62.8M | 2.04M | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 1000K | 0 | 0 | 0 | 1000K | 555K |
| Other Current Liabilities | 1.01M | 666K | 490K | 0 | 0 | 0 |
| Current Ratio | 0.27x | 5.69x | 14.28x | 8.90x | 5.71x | 5.37x |
| Quick Ratio | 0.16x | 4.97x | 13.44x | 8.02x | 5.02x | 4.48x |
| Cash Conversion Cycle | 302.45 | 274.69 | 257.49 | 271.96 | 256.11 | 241.49 |
| Total Non-Current Liabilities | 75.3M | 194.19M | 50.76M | 68.35M | 70.77M | 71.48M |
| Long-Term Debt | 0 | 50.82M | 49.85M | 52.91M | 56.95M | 59.52M |
| Capital Lease Obligations | 0 | 0 | 0 | 15.44M | 13.81M | 11.95M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 75.3M | 143.37M | 911K | 0 | 0 | 0 |
| Total Liabilities | 150.44M | 203.78M | 60.06M | 79.33M | 87M | 86.63M |
| Total Debt | 62.8M | 52.86M | 49.85M | 69.77M | 72.39M | 73.34M |
| Net Debt | 58.68M | 26.47M | 30.66M | 63.16M | 54.34M | 59.91M |
| Debt / Equity | - | - | 0.68x | 2.01x | 3.51x | 9.15x |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - |
| Interest Coverage | -2.32x | -1.14x | -3.20x | -5.42x | -3.19x | -2.46x |
| Total Equity | -129.35M | -147.83M | 73.5M | 34.78M | 20.65M | 8.01M |
| Equity Growth % | - | -0.14% | 1.5% | -0.53% | -0.41% | -0.61% |
| Book Value per Share | -11.65 | -13.31 | 4.43 | 1.41 | 0.80 | 0.28 |
| Total Shareholders' Equity | -129.35M | -147.83M | 73.5M | 34.78M | 20.65M | 8.01M |
| Common Stock | 1K | 0 | 24K | 25K | 28K | 30K |
| Retained Earnings | -363.64M | -387.69M | -423.77M | -470.85M | -503.81M | -530.95M |
| Treasury Stock | -73.57M | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 1K | 33K | -272K | -1.11M | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Cash from Operations | -25.03M | -21.61M | -24.58M | -36.87M | -19.7M | -17.95M |
| Operating CF Margin % | -0.68% | -0.53% | -0.54% | -0.81% | -0.3% | -0.22% |
| Operating CF Growth % | - | 0.14% | -0.14% | -0.5% | 0.47% | 0.09% |
| Net Income | -29.97M | -24.28M | -36.08M | -47.08M | -32.96M | -27.14M |
| Depreciation & Amortization | 421K | 312K | 296K | 2.99M | 1.6M | 1.77M |
| Stock-Based Compensation | 1.44M | 1.38M | 4.29M | 8.35M | 9.56M | 10.28M |
| Deferred Taxes | 0 | 0 | 5.48M | 0 | 0 | 0 |
| Other Non-Cash Items | 3.08M | 3.04M | 1.07M | 3.67M | 4.58M | 2.59M |
| Working Capital Changes | 9K | -2.07M | 368K | -4.79M | -2.48M | -5.45M |
| Change in Receivables | -750K | -2.38M | 1.3M | -391K | -4.85M | -537K |
| Change in Inventory | -1.64M | 672K | -1.16M | -2.13M | -1.7M | 251K |
| Change in Payables | -82K | -5K | 479K | 647K | 240K | 671K |
| Cash from Investing | 3.62M | -10.77M | -85.4M | 23.8M | 23.03M | 8.99M |
| Capital Expenditures | -468K | -62K | -384K | -603K | -173K | -306K |
| CapEx % of Revenue | 0.01% | 0% | 0.01% | 0.01% | 0% | 0% |
| Acquisitions | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - |
| Other Investing | 4K | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 21.37M | 55.01M | 102.53M | 490K | 8.13M | 4.33M |
| Debt Issued (Net) | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - |
| Other Financing | 42K | -1.15M | -2.47M | 490K | 239K | 1.05M |
| Net Change in Cash | - | - | - | - | - | - |
| Free Cash Flow | -25.49M | -21.67M | -24.96M | -37.47M | -19.87M | -18.25M |
| FCF Margin % | -0.69% | -0.53% | -0.55% | -0.82% | -0.3% | -0.23% |
| FCF Growth % | - | 0.15% | -0.15% | -0.5% | 0.47% | 0.08% |
| FCF per Share | -2.30 | -1.95 | -1.50 | -1.52 | -0.77 | -0.63 |
| FCF Conversion (FCF/Net Income) | 0.83x | 0.89x | 0.68x | 0.78x | 0.60x | 0.66x |
| Interest Paid | 5.42M | 4.41M | 0 | 4.46M | 4.48M | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -49.09% | -86.96% | -118.91% | -189.35% |
| Return on Invested Capital (ROIC) | - | - | - | -30.28% | -23.57% | -22.75% |
| Gross Margin | 71.58% | 73.59% | 74% | 71.38% | 73.56% | 73.94% |
| Net Margin | -81.07% | -59.02% | -79.85% | -103.43% | -50.38% | -33.97% |
| Debt / Equity | - | - | 0.68x | 2.01x | 3.51x | 9.15x |
| Interest Coverage | -2.32x | -1.14x | -3.20x | -5.42x | -3.19x | -2.46x |
| FCF Conversion | 0.83x | 0.89x | 0.68x | 0.78x | 0.60x | 0.66x |
| Revenue Growth | - | 11.27% | 9.83% | 0.75% | 43.72% | 22.14% |
| 2023 | 2024 | |
|---|---|---|
| Non-US | 100K | 200K |
| Non-US Growth | - | 100.00% |
NeuroPace, Inc. (NPCE) reported $94.9M in revenue for fiscal year 2024. This represents a 157% increase from $37.0M in 2019.
NeuroPace, Inc. (NPCE) grew revenue by 22.1% over the past year. This is strong growth.
NeuroPace, Inc. (NPCE) reported a net loss of $24.0M for fiscal year 2024.
NeuroPace, Inc. (NPCE) has a return on equity (ROE) of -189.4%. Negative ROE indicates the company is unprofitable.
NeuroPace, Inc. (NPCE) had negative free cash flow of $16.6M in fiscal year 2024, likely due to heavy capital investments.